KLK3 and posterior cortical atrophy: In addition, approximately 20% of PCa cases are accompanied by neuroendocrine alterations during the treatment course [11], which is associated with difficulty in assessing disease progression solely based on PSA levels [12–15], suggesting that the evaluation of PSA levels is not sufficient to accurately predict BM status [16, 17].